Randomized Clinical Trials (RCTs): Five RCTs have been conducted, all reporting that TNF-α inhibitors positively impact the progression of atherosclerosis in patients with psoriasis, PsA, and other rheumatoid diseases [15, 23–26]. This evidence concerns the gene TNF and atherosclerosis.